HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

AARP data show U.S. drug prices rise postlaunch as foreign prices fall

AARP found top U.S. brand-name drugs climbed 81% in list price since launch while prices abroad fell 13%, hinting at the early reach of Medicare negotiations.

By RxInsider Editorial · Jun 1, 2026 · 330 words · via FiercePharma
AARP data show U.S. drug prices rise postlaunch as foreign prices fall

Image: FiercePharma

The AARP Public Policy Institute found that list prices for 25 leading brand-name drugs have soared an average of 81% in the U.S. since launch, while dropping 13% across 19 peer nations through April 1, 2026. These therapies represented more than $100 billion in 2024 Medicare Part D spending for around 15 million beneficiaries. The disparities were striking. Amgen’s Enbrel rose 873% in the U.S. but fell 27% abroad. Incyte’s Jakafi gained 160% domestically, slipping 9% overseas, and Merck’s Januvia climbed 126% in the U.S. yet dropped 40% internationally. The lone exception: Amgen’s Repatha, which fell below its launch price after a 2018 cut. Six drugs currently under Medicare negotiation trimmed list prices by roughly 40% between 2024 and 2026. Still, AARP said the overall U.S. trend line points higher.

That divergence underscores how the structural rules differ between American and foreign pricing systems. In the U.S., drugs launch high and keep rising; in most peer markets, price reviews eventually drive them down. Early reductions among the Medicare-negotiated products indicate that the Inflation Reduction Act’s new authority is already shifting postlaunch behavior. Whether it becomes a broad correction or stays limited to a few high-profile categories is unclear, the data remains mixed. But with the White House pushing for Most Favored Nation-style benchmarks, the groundwork for a market adjustment is visible, especially where Medicare Part D dominates sales volume.

For investors, the message cuts two ways. Aging brands face real erosion in postlaunch pricing power as negotiation expands, while global firms must manage a widening gap between U.S. and ex-U.S. margins that can’t be leveled by simple rebate tactics anymore. Payers will use this data to negotiate more aggressively, pressing for larger concessions or tighter formularies. If 2026 ends up as the first year of sustained list-price decline for these benchmark drugs, it could reset commercial expectations entirely. Or not, but either way, the market is watching closely. For deeper comparisons on PBM and employer pricing strategies, see RxPBM.ai.

Tags
theweekformat:briefingsynthesispharmatrade
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
The WeekFiercePharma ↗
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
Jun 1, 2026
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
The WeekFierceBiotech ↗
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
Jun 1, 2026
STAT+: A standing ovation for RevMed, and caution for Akeso
The WeekSTAT News ↗
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immun…
May 31, 2026